Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

Blood

Volumn 100, Issue 1, 2002, Pages 59-66

  Schnittger, Susanne ^a,b,c,d,e,f   Schoch, Claudia ^a,b,c,d,e   Dugas, Martin ^a,b,c,d,e   Kern, Wolfgang ^a,b,c,d,e   Staib, Peter ^a,b,c,d,e   Wuchter, Christian ^a,b,c,d,e   Löffler, Helmut ^a,b,c,d,e   Sauerland, Cristina Maria ^a,b,c,d,e   Serve, Hubert ^a,b,c,d,e   Büchner, Thomas ^a,b,c,d,e   Haferlach, Torsten ^a,b,c,d,e   Hiddemann, Wolfgang ^a,b,c,d,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER REGRESSION; CHROMOSOME ABERRATION; CHROMOSOME MUTATION; CYTOGENETICS; DISEASE MARKER; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SURVIVAL;

EID: 0036659931     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.59     Document Type: Article

References (49)

1. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. J Clin Oncol. 1999;10:1419-1432.
2. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
3. Caligiuri MA, Strout MP, Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol. 1997;24:32-44.
4. Look AT, Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064.
5. Schoch C, Haferlach T, Bursch S, Schnittger S, Hiddemann W. Resolving complex aberrant karyotypes in acute myeloid leukemia with 24 color FISH: a study of 89 cases [abstract]. Blood. 2000;96(suppl 1):4405.
6. Schichman SA, Caligiuri MA, Strout MP, et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res. 1994;54:4277-4280.
7. Yu M, Honoki K, Andersen J, Paietta E, Nam DK, Yunis JJ. MLL tandem duplication and multiple splicing in adult acute myeloid leukemia with normal karyotype. Leukemia. 1996;10:774-780.
8. Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58:55-59.
9. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56:1418-1425.
10. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identifies a prognostically unfavorable subset of AML. Leukemia. 2000;14:796-804.
11. Poirel H, Rack K, Delabesse E, et al. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood. 1996;87:2496-2505.
12. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
13. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
14. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337.
15. Lisovsky M, Estrov Z, Zhang X, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996;88:3987-3997.
16. Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000;108:322-330.
17. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96: 3907-3914.
18. Tse K-F, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2001;14:1766-1776.
19. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematopoietic malignancies. Blood. 2001;97:2434-2439.
20. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of a novel FLT3 Asp835 mutation in adult acute myeloid leukaemia. Br J Haematol. 2001;113:983-988.
21. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
22. Rombouts WJC, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia. 2001;14:675-683.
23. Kondo M, Horibe K, Takahashi Y, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol. 1999;33:525-529.
24. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94.
25. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
26. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
27. Büchner T, Hiddemann W, Wormann B. Intensive consolidation versus prolonged maintenance following intensive induction and conventional consolidation in primary AML: a study by AMLCG [abstract]. Blood. 2001;88(suppl 1):214.
28. ISCN. Guidelines for cancer cytogenetics. ISCN. 1995.
29. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucle. ated cells. Nucleic Acids Res. 1988;16:1215-1216.
30. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia: Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11:1447-1452.
31. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457.
32. Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155-162.
33. Johansson B, Mertens F, Mitelman F. Primary vs. secondary neoplasia-associated chromosomal abnormalities-balanced rearrangements vs. genomic imbalances? Genes Chromosomes Cancer. 1996;16:155-163.
34. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
35. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-a, in acute myeloid leukemia. Nat Genet. 2001;27:263-270.
36. Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442-1446.
37. Johansson B, Mertens F, Mitelman F. Secondary chromosomal abnormalities in acute leukemias. Leukemia. 2001;8:953-956.
38. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;15:726-727.
39. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia: Australian Leukaemia Study Group. Blood. 1994;84:1220-1225.
40. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol. 1997;24:57-69.
41. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190-195.
42. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia: German AML Cooperative Group. Leukemia. 2000;14:1362-1370.
43. Garson OM, Hagemeijer A, Sakurai M, et al. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genet Cytogenet. 1989;40:187-202.
44. Estey E, Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia. 1995;9:972-976.
45. Kern W, Schoch C, Hiddemann W. Prognostic significance of cytogenetics in relapsed acute myeloid leukaemia [letter]. Br J Haematol. 2000;109:671-672.
46. Nakano Y, Kiyoi H, Miyawaki S, et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol. 1999;104:659-664.
47. Thiede C, Steudel C, Mohr B, et al. Quantitative determination of FLT3 internal tandem repeat mutations defines a subgroup with poor prognosis in intermediate risk AML patients [abstract]. Blood. 2000;96(suppl 1):2334.
48. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer Leukemia Group B Study. Cancer Res. 2001;61:7233-7239.
49. Zhao M, Kiyoi H, Yamamoto Y, et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 2000;14:374-378.